Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is proud to announce a milestone funding achievement of 1,150,000,000 dollars that will significantly bolster our growth strategy and innovation drive. Founded in July 1995, Hansoh has steadily evolved into a leading pharmaceutical powerhouse in China, integrating research and development, manufacturing, sales, and pharmaceutical investment. Over the years, our organization has launched more than 40 market-ready products across six key therapeutic areas—including oncology, antibiotics, psychotropic, antidiabetics, gastro-intestinal, and cardiovascular treatments—cementing our position as one of China's top 30 pharmaceutical enterprises and a beacon of cutting-edge innovation.
This substantial infusion of capital will serve multiple strategic purposes. Primarily, it is earmarked for enhancing our research and development capabilities, enabling us to further our mission of delivering pioneering therapies that address some of today’s most challenging health conditions. The funding will also be used to expand our manufacturing facilities and improve production efficiencies through lean manufacturing practices, ensuring that we maintain the highest quality standards while meeting growing demand. Moreover, the investment will facilitate deeper collaborations with international partners, accelerating our journey towards becoming a global leader in pharmaceutical innovation. With an unwavering commitment to management, technology, and product innovation, Hansoh is poised to collect top-level talent and integrate advanced technology to continue pushing the boundaries of what is possible in healthcare.
We extend our gratitude to our investors and partners for their trust and support as we embark on this transformative phase. Together, we are confident that our forward-looking strategies and relentless pursuit of excellence will contribute significantly to the global betterment of health and wellness.
